RxDoctor Payments Data

Ashwini Reddy, MD

Internal Medicine · Englewood, CONPI 1891834727

Payments from drug & device makers

$6,453in general payments, 2019–2025

Across 322 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$930
  • AstraZeneca$760
  • Pfizer$743
  • Amgen$705
  • Astellas Pharma US Inc$581
  • Novo Nordisk$484
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$6,19496%
  • Education$2594%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,453 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$73,876
Medicare patients
186
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$87,530
XareltoRivaroxaban30$49,552
MounjaroTirzepatide44$46,812
OzempicSemaglutide38$35,218
BelsomraSuvorexant28$14,796
EntrestoSacubitril/Valsartan15$14,305
MyrbetriqMirabegron13$13,540
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,411
Fluticasone-SalmeterolFluticasone Propion/Salmeterol48$7,446
Spiriva HandihalerTiotropium Bromide12$6,184
Estradiol49$4,694
Levothyroxine Sodium461$4,488
Atorvastatin Calcium495$4,220
Arnuity ElliptaFluticasone Furoate12$3,418
SynthroidLevothyroxine Sodium60$3,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$743$87,53072 claims
Johnson & JohnsonXarelto$129$49,55230 claims
Lilly USA, LLCMounjaro$219$46,81244 claims
Novo NordiskOzempic$484$35,21838 claims
GSKTrelegy Ellipta, Arnuity Ellipta$322$15,82929 claims
MerckBelsomra$159$14,79628 claims
NovartisEntresto$33$14,30515 claims
Astellas Pharma US IncMyrbetriq$581$13,54013 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$52$4,488461 claims
AbbVieSynthroid$930$3,36060 claims
IBSA Pharma Inc.Tirosint$13$1,69612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Englewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →